Get started
Author

T. Beninato

Observed names: Taoyuan Beninato, Taoyuan M Beninato
OpenAlex ID: A5129741852
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
2024 · C. Proto, M. Ganzinelli, et al. · Annals of Oncology · 43
PDF
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
2022 · E.G. Pizzutilo, A.G. Agostara, et al. · Journal of Thoracic Oncology · 5
PDF
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records
2025 · L. Mazzeo, F. Corso, et al. · ESMO Real World Data and Digital Oncology · 3
PDF
Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer
2025 · L. Provenzano, M. Favali, et al. · ESMO Real World Data and Digital Oncology · 2
PDF
117P Predicting immunotherapy response in non-small cell lung cancer using a foundation model for tabular data and real-world clinical evidence: Insights from APOLLO11 study
2025 · C.M. Licciardello, A. Ferrarin, et al. · ESMO Real World Data and Digital Oncology · 1
PDF
40P: Metformin plus/minus cyclic fasting mimicking diet to improve the efficacy of first-line chemo-immunotherapy in advanced LKB1-inactive NSCLC: Results of the phase II trial FAME
2025 · M. Occhipinti, M. Brambilla, et al. · Journal of Thoracic Oncology · 1
PDF
415P: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: Insights from the pembrolizumab 5-year global registry
2025 · A. Cortellini, E. Garbo, et al. · Journal of Thoracic Oncology · 1
PDF
P2.11B.03 Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy
2024 · R. Ferrara, T. Torelli, et al. · Journal of Thoracic Oncology · 1
PDF
MO13.06: A Triage-Aware Neuro-Symbolic Platform for Safe Lung Cancer Trial Matching
2026 · V. Peppoloni, G. Leone, et al. · Journal of Thoracic Oncology
P1.282: Evaluating Clinical Alignment of AI Explanations in Text-Based Immunotherapy Response Prediction for NSCLC
2026 · A. Ferrarin, T. Arangoa, et al. · Journal of Thoracic Oncology
MO04.02: Relevent Trial: Updated Survival Outcomes of Ramucirumab in Combination With Chemotherapy in Untreated Advanced Thymic Carcinoma
2026 · C. Proto, M. Ganzinelli, et al. · Journal of Thoracic Oncology
P3.376: Reduced MTAP and CDKN2A mRNA Expression Is Associated With Poor Outcome in Pleural Mesothelioma
2026 · P. Ambrosini, G. Farhikhteh, et al. · Journal of Thoracic Oncology
P2.227: Clinical Fragility and Prognostic Stratification in STK11/LKB1 Impaired NSCLC: Insights From a Real-World Cohort
2026 · M. Ganzinelli, M.P. Di Palma, et al. · Journal of Thoracic Oncology
42P B7-H3 defines an aggressive molecular subtype of pleural mesothelioma characterized by immune exclusion and EMT
2026 · P. Ambrosini, L.M. Invernizzi, et al. · ESMO Open
17RO Comprehensive genomic profiling of pleural mesothelioma unveils potential targets within a molecular tumor board framework
2026 · D. Lorenzini, P. Ambrosini, et al. · ESMO Open
PDF
478P Explainable machine learning analysis reveals neutrophil dynamics as predictor of immunotherapy response in advanced NSCLC
2026 · C. Silvestri, A. Rigamonti, et al. · ESMO Open
PDF
267P Chronobiology as prognostic factor in resected stage I NSCLC
2026 · G. Leuzzi, C. Proto, et al. · ESMO Open
305P Role of the pan-immune-inflammatory value in stage III NSCLC treated with chemoradiotherapy with or without durvalumab
2026 · G. Montelatici, G. Gronchi, et al. · ESMO Open
PDF
512P Molecular landscape of BRCA-mutated NSCLC
2026 · D. Lorenzini, A. Busico, et al. · ESMO Open
PDF
97P Multimodal AI models integrating clinical and CT imaging data to predict survival outcomes in immunotherapy-treated NSCLC: Results from the multicentric APOLLO11 study
2026 · V. Miskovic, C.M. Licciardello, et al. · ESMO Open
331P Prognostic impact of B7-H3 (CD276) RNA expression in pleural mesothelioma
2026 · P. Ambrosini, G. Farhikhteh, et al. · ESMO Open
559eP Thoracic malignancies in adolescents and young adults (AYA): A single-center cohort
2026 · C. Cavalli, S. Marchesi, et al. · ESMO Open
280P Survival patterns in large-cell neuroendocrine carcinoma: Impact of histology, molecular features, and immunotherapy
2026 · F. Bertuzzi, G. Nardo, et al. · ESMO rare cancers.
PDF
284P Thoracic NUT carcinoma and SMARCA4-deficient undifferentiated tumor: Clinical management and outcomes from two Italian referral centers
2026 · A. Bassetti, M. Giammaruco, et al. · ESMO rare cancers.
OA09.02 I3LUNG-PDSS: A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC
2025 · A. Prelaj, V. Mišković, et al. · Journal of Thoracic Oncology
Works count: 38
Citation count: 57
H-index: 3
I10-index: 1
Year
Topic
Type